Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients
Authors:
- 12 December 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 15 (2) , 93-110
Abstract
Introduction: Human herpesviruses frequently cause infections in solid organ transplant (SOT) recipients. Areas covered: We provide an overview of the clinical impact of alpha and beta herpesviruses and highlight the mechanisms of action, pharmacokinetics, clinical indications, and adverse effects of antiviral drugs for the management of herpes simplex virus, varicella zoster virus and cytomegalovirus. We comprehensively evaluated key clinical trials that led to drug approval, and served as the foundation for management guidelines. We further provide an update on investigational antiviral agents for alpha and beta herpesvirus infections after SOT. Expert commentary: The therapeutic armamentarium for herpes infections is limited by the emergence of drug resistance. There have been major efforts for discovery of new drugs against these viruses, but the results of early-phase clinical trials have been less than encouraging. We believe, however, that more antiviral drug options are needed given the adverse side effects associated with current antiviral agents, and the emergence of drug-resistant virus populations in SOT recipients. Likewise, optimized use and strategies are needed for existing and novel antiviral drugs against alpha and beta-herpesviruses in SOT recipients.Keywords
This publication has 186 references indexed in Scilit:
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationTransplantation, 2013
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Human Herpesviruses 6, 7 and 8 in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2013
- Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant PatientsAmerican Journal of Transplantation, 2013
- Overview: Cytomegalovirus and the Herpesviruses in TransplantationAmerican Journal of Transplantation, 2013
- Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised PatientsTransplantation and Cellular Therapy, 2012
- Chromosomally integrated human herpesvirus 6: questions and answersReviews in Medical Virology, 2011
- Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution StudiesThe Journal of Infectious Diseases, 2010
- CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999